Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2022 · 10-Q
Revenue$16.73M$16.73M−5.5% vs Q2 2021 Net Income-$6.40M-$6.40MN/M vs Q2 2021 EPS Diluted-$0.09-$0.09N/M vs Q2 2021 Gross Profit$10,042,000−7.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,832,000N/M Margins · derivedGross margin60.0%−1.1 pt vs Q2 2021
Operating margin-38.2%−6.8 pt vs Q2 2021
Net margin-38.2%−6.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end